Attached files

file filename
10-Q - 10-Q - PRECISION BIOSCIENCES INCdtil-10q_20200930.htm
EX-32.1 - EX-32.1 - PRECISION BIOSCIENCES INCdtil-ex321_9.htm
EX-31.2 - EX-31.2 - PRECISION BIOSCIENCES INCdtil-ex312_8.htm
EX-31.1 - EX-31.1 - PRECISION BIOSCIENCES INCdtil-ex311_7.htm
EX-10.2 - EX-10.2 - PRECISION BIOSCIENCES INCdtil-ex102_284.htm
EX-10.1 - EX-10.1 - PRECISION BIOSCIENCES INCdtil-ex101_32.htm
EX-3.3 - EX-3.3 - PRECISION BIOSCIENCES INCdtil-ex33_816.htm
EX-3.2 - EX-3.2 - PRECISION BIOSCIENCES INCdtil-ex32_377.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Precision BioSciences, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: November 10, 2020

By:

/s/ Abid Ansari

 

 

Abid Ansari

 

 

Chief Financial Officer

(principal financial officer)